SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to a mixed reaction to earnings, with initial positive revenue overshadowed by a one-time tax charge and concerns about increased spending on AI infrastructure. The community is debating whether the dip is a buying opportunity or a sign of deeper issues with the company's investment strategy. Some investors believe the market is overreacting, while others are wary of Meta's increasing capital expenditures.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid anticipation for an upcoming meeting between President Trump and China's President Xi, with trade deal hopes influencing market sentiment. Community members are actively discussing potential impacts on major tech companies following mixed earnings reports from key players like Microsoft and Meta, while some express concern about an over-reliance on a few top stocks. Investors are weighing the potential for further market gains against concerns about stretched valuations and the broader economic outlook.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending downwards due to concerns raised after recent earnings, including lowered sales outlooks and declining customer traffic, leading to community frustration over the company's future. The community expresses concerns about high prices, smaller portions, and declining food quality potentially driving customers away. Some investors speculate on potential bottom prices, while others express optimism regarding possible institutional buying and long-term growth despite current challenges.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending downwards after a significant earnings miss and slashed guidance, prompting analyst downgrades and heavy discussion of potential corporate fraud. The community is debating whether the steep drop represents a buying opportunity or a sign of deeper issues, with some pointing to management changes and oversold conditions as potential catalysts for a rebound. Discussions also involve the company's long-term debt and a potential shift to the NASDAQ.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending amid discussions surrounding its recent earnings report and forward guidance, with some investors expressing concern about increased spending on AI and its impact on profitability.  Community talking points include the company's Azure cloud growth, its stake in OpenAI, and reactions to the Trump-Xi meeting. The stock's movement is also being discussed in the context of broader market trends and the performance of other tech giants.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it surpasses a $5 trillion market cap, fueled by exceptionally strong AI chip demand and CEO Jensen Huang's forecast of $500 billion in cumulative revenue through 2026; the community is closely watching Trump's upcoming meeting with President Xi for potential easing of China's Blackwell restrictions, while also weighing the potential impact of increased capex from major tech companies like Microsoft and Meta.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending amid ongoing speculation about a potential merger with Warner Bros. Discovery ($WBD), with discussions focusing on offer prices and deal structures. Community chatter revolves around whether a deal will materialize and its potential impact, particularly as analysts debate the value and future of the combined entity, while others point to upcoming earnings and layoffs as key events to watch.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet's stock is trending as traders discuss the company's recent earnings beat and growing excitement around its AI and cloud computing initiatives. Community members are highlighting Google's AI strategy and potential for further growth, particularly compared to other tech giants. Some are also discussing the impact of Google's capital expenditure plans and partnerships in the AI space.

SSgA Active Trust - Financial Select Sector SPDR

Financial Select Sector SPDR Fund

The XLF is trending amid discussions about potential breakouts and pullbacks, with community members analyzing its structure using Elliott Wave theory. Some traders are highlighting potential buying opportunities in specific zones while others express caution, noting overbought conditions and potential resistance levels. Broader market concerns, including the Federal Reserve's actions and the health of the financial sector, are also influencing the conversation around XLF.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Enthusiasm around Alphabet is surging as Q3 earnings approach, with analysts citing AI advancements and cloud growth as key drivers. The community is closely watching for a breakout, with some anticipating a significant move towards $300, while others remain cautious of a potential pullback after earnings. Talk of cloud and AI dominance is fueling optimism, as well as the settlement of legal issues.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Crinetics Pharmaceuticals picked up on Thursday after the U.S. Food and Drug Administration approved its lead therapy Palsonify (paltusotine) for adults with acromegaly.<a href="https://stocktwits.com/symbol/CRNX">Crinetics’ stock</a> closed Thursday up 2.02% at $35.89 and added another 0.8% in after-hours trading.The once-daily oral treatment is the first of its kind to be cleared in the U.S. for patients who do not respond to surgery or are unable to undergo surgery. The FDA decision was supported by two pivotal Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, in which Palsonify was well-tolerated, provided rapid and durable biochemical control, and reduced symptom burden. Patients reported improvements in headaches, fatigue, joint pain and swelling.Crinetics released&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crinetics-pharma-s-oral-drug-shows-lasting-relief-for-acromegaly-patients-in-latest-study-retail-buzz-builds/ch8B1oBR5Nq">long-term data in July</a> from the same studies, showing that patients who switched from monthly injections to Palsonify were able to maintain steady hormone levels for nearly two years.&nbsp;Symptom flares fell significantly, from more than 30% of days on injectable therapies to just 6.2% on stable Palsonify dosing.&nbsp;CEO Scott Struthers called the FDA approval a “new era” for patients and the company, marking the first product launch from its pipeline of small-molecule drugs. The company said Palsonify will be available in the U.S. in early October, supported by a patient services program called CrinetiCARE.Paltusotine is also being evaluated for the treatment of carcinoid syndrome in the pivotal Phase 3 CAREFNDR trial, with global enrollment expected throughout 2025.On Stocktwits, retail sentiment for Crinetics was ‘extremely bullish’ amid a 410% surge in 24-hour message volume, placing it among the top three trending equities on the platform.&nbsp;Users expressed relief after a discussion clarified that while Crinetics sources some ingredients from Europe and previously India, its final tablets are manufactured in the United States, reducing tariff concerns.<stembedurl>https://stocktwits.com/Market_Luther_Kang/message/630073335</stembedurl>Another user remarked that the overwhelmingly positive news, combined with a temporary trading halt, suggested a significant price increase for Crinetics stock could be expected.<stembedurl>https://stocktwits.com/hobbytrader2/message/630067465</stembedurl>Crinetics Pharmaceuticals’ stock has declined 29.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Crinetics Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move

The company plans to launch in the U.S. in early October, with a European launch expected in 2026.

Equity

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral acromegaly drug candidate, Palsonify (paltusotine), showing sustained biochemical control and symptom relief across two Phase 3 studies.At the ENDO 2025 conference, Crinetics shared new data from its ongoing PATHFNDR-1 and PATHFNDR-2 studies, showing that patients who switched from monthly injections to once-daily oral Palsonify were able to keep their insulin-like growth factor 1 (IGF-1) and growth hormone levels steady for nearly two years.&nbsp;Symptom scores, based on the acromegaly symptom diary (ASD), also remained stable. Palsonify was generally well tolerated.In PATHFNDR-2, which studied patients with uncontrolled acromegaly, Palsonify led to sustained reductions in IGF-1 and symptom flares through 84 weeks.&nbsp;Notably, patients who had previously been on placebo experienced meaningful improvements after switching to Palsonify in the open-label extension (OLE).A pooled analysis of symptom scores across both studies showed a significant decrease in day-to-day symptom flares for patients switching from injectables from over 30% of days on somatostatin receptor ligand (SRL) to just 6.2% during stable Palsonify dosing, regardless of baseline control or treatment history.CEO Scott Struthers said the data reinforce Palsonify’s potential as a once-daily, next-generation treatment for acromegaly.&nbsp;Crinetics is also advancing Palsonify in a Phase 3 trial for carcinoid syndrome in patients with neuroendocrine tumors, following promising Phase 2 results in flushing and bowel movement control.In March, the European Medicines Agency (EMA) validated Crinetics' marketing authorization application (MAA) for Palsonify as a long-term maintenance therapy for acromegaly.&nbsp;The EMA had previously granted the drug Orphan Drug Designation in February.&nbsp;On Stocktwits, retail sentiment for Crinetics was ‘bullish’ amid ‘high’ message volume.Crinetics’ stock has declined 38.1% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trumps-35-tariff-threat-ripples-through-walmart-s-bangladesh-supply-chain-report/ch8B1KwR5Np">Trump’s 35% Tariff Threat Ripples Through Walmart’s Bangladesh Supply Chain: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Crinetics Pharmaceuticals' (CRNX) Palsonify (paltusotine) showed sustained biochemical control and symptom relief across two Phase 3 studies. (Photo credit: Getty Images)

Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds

The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two years. 

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?

Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Futures Drop On DOJ's Google Crackdown, China Plunge

Futures Drop On DOJ's Google Crackdown, China Plunge

 US equity futures are lower on news that the DOJ is considering a breakup of Alphabet's Google search engine, in what would be a...

Strong Future for Crinetics Pharmaceuticals: A Comprehensive Buy Rating Justification

Crinetics Pharmaceuticals (CRNX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan W...

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals

Latest Ratings for CRNX
 DateFirmActionFromTo Nov 2021JMP SecuritiesInitiates Coverage OnMarket Outperform Nov 2021Evercore ISI GroupInitiates Coverage OnOutperform Nov 2021HC Wainwright...

17 Analysts Have This To Say About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.24	--	--	N/A
Q2 '25	-$1.08	-$1.23	-13.73%	MISSED
Q1 '25	-$0.94	-$1.04	-10.54%	MISSED
Q4 '24	-$0.89	-$0.88	0.69%	BEAT
Q3 '24	-$0.91	-$0.96	-5.42%	MISSED

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest CRNX News

CRNXCrinetics Pharmaceuticals Inc